Publications
968
Citations
75,635
Est. group size
~6
Recurring co-author estimate
Active years
53
Publishing since 1974
Typically publishes in teams of ~7 · 22% small-team papers (≤3 authors) · across 88 venues
- International development of a lupus-specific instrument to assess cognitive symptoms in patients with SLE: Lupus Brain Fog Severity Scale (LBFSS) study
Lupus Science & Medicine · 2026
- ERN ReCONNET–SLICC–SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations
The Lancet Rheumatology · 2025
- Direct oral anticoagulants versus Vitamin K antagonists in antiphospholipid syndrome: A systematic review and meta-analysis
Seminars in Arthritis and Rheumatism · 2025
- Predictors of Mortality in Antiphospholipid Antibody–Positive Patients: Prospective Results From Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository
Arthritis Care & Research · 2025
- Anti-TFAM antibodies link mitochondrial damage with antiphospholipid syndrome and thrombosis in SLE
Annals of the Rheumatic Diseases · 2025
- Role of Prednisone and 25‐Hydroxyvitamin D on Bone Mineral Density and Osteoporosis in Systemic Lupus Erythematosus
Arthritis Care & Research · 2025
- DESIGN OF A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MK-6194, AN INTERLEUKIN-2 MUTEIN, IN ADULT PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
The Journal of Rheumatology · 2025
- Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries
The Lancet Rheumatology · 2025
- Development of the 2023 <scp>ACR</scp> / <scp>EULAR</scp> Antiphospholipid Syndrome Classification Criteria, Phase <scp>III</scp> ‐C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions
Arthritis Care & Research · 2025
- Preload deficiency as a treatable cause of fatigue and exercise intolerance in SLE
The Lancet Rheumatology · 2025
- Genetic and Epigenetic Dysregulation of CR1 is Associated with Catastrophic Antiphospholipid Syndrome (CAPS)
medRxiv · 2025
- MACHINE LEARNING CAN IDENTIFY AN ANTINUCLEAR ANTIBODY PATTERN THAT MAY RULE OUT SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES
The Journal of Rheumatology · 2025
- OP0201 ACHIEVEMENT OF LOW DISEASE ACTIVITY AND REMISSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH DAPIROLIZUMAB PEGOL: 48-WEEK RESULTS FROM A PHASE 3 TRIAL
Annals of the Rheumatic Diseases · 2025
- POS0734 DAPIROLIZUMAB PEGOL DEMONSTRATED SIGNIFICANT IMPROVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY: EFFICACY AND SAFETY RESULTS OF A PHASE 3 TRIAL
Annals of the Rheumatic Diseases · 2025
- Incidence And Predictors Of Recurrent Pericarditis In A Longitudinal Lupus Cohort
Journal of Cardiac Failure · 2025
- Annals of the Rheumatic Diseases×82
- Lupus Science & Medicine×41
- Arthritis & Rheumatology×31
- Arthritis Care & Research×31
- Lupus×23
- Wendy Marder
Medicine · University of Michigan
- Emily C. Somers
Medicine · University of Michigan
- W. Joseph McCune
Medicine · University of Michigan
- Jessica Greco
Medicine · The Ohio State University
- Ajay Tambralli
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile